Showing 171-180 of 5059 results for "".
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- Survey Reveals Attitudes About Lip Healthhttps://practicaldermatology.com/news/survey-reveals-attitudes-about-lip-health/2458937/The majority of Americans suffer from dry and chapped lips, and 1 in 4 say that when their lips are chapped and flaky they don’t look attractive. Furthermore, close to 1 in 5 say their self-confidence goes down when their lips are chapped and flaky and, some even
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim
- EWG Releases 2012 Sunscreen Guide and Apphttps://practicaldermatology.com/news/20120608-ewg_releases_2012_sunscreen_guide_and_app/2459787/After rating 257 brands and more than 1,800 products, the Environmental Working Group (EWG) released its sixth annual Guide to Summer Sun. EWG recommends 1 in 4 of more than 800 beach and sport sunscreens, compared to 1 in 5 l
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 v
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- Novartis Set to Acquire Calypso Biotech, Focused on IL-15 Targeted Therapieshttps://practicaldermatology.com/news/novartis-set-to-acquire-calypso-biotech-focused-on-il-15-targeted-therapies/2462204/European-based biotech manufacturer Calypso has entered into an agreement to be acquired by Novartis, according to a press release. "We are excited for this transaction with Novartis," Calypso CEO and Founder Alain Vicari said in a news release. "As part of the
- FDA Approves Novartis Cosentyx as First IV Formulation IL-17A Antagonist for PsAhttps://practicaldermatology.com/news/fda-approves-novartis-cosentyx-as-first-iv-formulation-il-17a-antagonist-for-psa/2462048/The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Novartis’ Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx
- Industry Responds to COVID-19: NoSweathttps://practicaldermatology.com/news/industry-responds-to-covid-19-nosweat/2460695/Recognizing that any physical activity coupled with wearing a face shield can produce sweat that can get in the eyes and fog-up shields, NoSweat has created the first disposable performance liners specifically for face shields that absorb sweat while preventing fogging, odors, stains, and even ac
- Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitishttps://practicaldermatology.com/news/novartis-enters-licensing-deal-for-il-17c-compound-for-atopic-dermatitis/2457689/Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novarti